cbd dosage for dravets

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

ABSTRACT Pure, plant-based CBD is a pharmaceutical grade extract that exhibits clinically significant antiseizure properties, with a hypothesized multimodal mechanism of action. In the GWPCARE trial series, CBD displayed superior efficacy in reducing key seizure frequencies (convulsive seizures in DS; drop seizures in LGS) by 17% to 23% compared with placebo as adjunctive therapy to …

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes Read More »

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

ABSTRACT By November 2016, a total of 278 patients had completed the original randomized trials, and 264 (95%) enrolled in this open-label extension. Median treatment duration was 274 days (range 1-512) with a mean modal dose of 21 mg/kg/d, and patients received a median of 3 concomitant antiepileptic medications. Adverse events (AEs) occurred in 93.2% …

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial Read More »

Cannabidiol Oil Safely Lessens Seizures in Treatment-resistant Children, Early Trial Data Show

ABSTRACT A team led by researchers at University of Saskatchewan, Canada, are conducting an open-label Phase 1 clinical study (NCT03024827) called CARE-E. Scientists are exploring the safety and impact of increasing doses of CBD-enriched cannabis herbal extract (CHE) used as add-on therapy in up 28 children (ages 1 to 10) with epileptic encephalopathy resistant to …

Cannabidiol Oil Safely Lessens Seizures in Treatment-resistant Children, Early Trial Data Show Read More »

Scroll to Top
Scroll to Top